TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

ASTELLAS

OncologyGastroenterologyMetabolic
Specialty

ASTELLAS is a specialty pharmaceutical company focused on Oncology, Gastroenterology, Metabolic. Key products include XTANDI.

1957
Since
23
Drugs
-
Trials
18
Approved (2yr)

Key Drugs

XTANDI
enzalutamide
Oncology
Androgen Receptor 3 indications · 2012
IZERVAY
avacincaptad pegol sodium
Ophthalmology
Complement C5 2 indications · 2023
CRESEMBA
isavuconazonium sulfate
2 indications · 2015
ASTAGRAF XL
tacrolimus
Calcineurin 1 indications · 2013
VEOZAH
fezolinetant
NK3R 1 indications · 2023

Recent Activity

XTANDI 2025-12-11
Labeling
XTANDI 2025-12-11
Labeling
PADCEV 2025-11-21
Efficacy
VYLOY 2025-06-06
Efficacy
CRESEMBA 2025-03-24
Labeling
CRESEMBA 2025-03-24
Labeling
XTANDI 2025-03-21
Labeling
XTANDI 2025-03-21
Labeling
PADCEV 2025-02-27
Labeling
IZERVAY 2025-02-12
Efficacy
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 63%
3 drugs Phase 3: 12 Phase 2: 13 Phase 1: 48
Gastroenterology 12%
1 drugs Phase 3: 3 Phase 2: 1 Phase 1: 6
Metabolic 9%
0 drugs Phase 3: 3 Phase 2: 3 Phase 1: 2
Ophthalmology 9%
1 drugs Phase 3: 1 Phase 2: 3 Phase 1: 3
Immunology 8%
0 drugs Phase 3: 2 Phase 2: 3 Phase 1: 3

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Oncology, Immunology, Gastroenterology
Takeda big-pharma
Immunology, Oncology, Gastroenterology, Metabolic
Novartis big-pharma
Oncology, Immunology, Ophthalmology
Merck big-pharma
Oncology, Immunology, Metabolic
AbbVie big-pharma
Immunology, Oncology, Ophthalmology